首页> Frontiers in pharmacology> Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers.

Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers.

导出 LinkOut

翻译打印收藏纠错

第一作者： Xiaojiao,Li

第一单位： Phase I Clinical Trial Unit, First Hospital, Jilin University, Jilin, China.

作者： Xiaojiao,Li ^[1] ; Cai,Liu ^[2] ; Xiaoxue,Zhu ^[1] ; Haijing,Wei ^[1] ; Hong,Zhang ^[1] ; Hong,Chen ^[1] ; Guiling,Chen ^[1] ; Deming,Yang ^[1] ; Hongbin,Sun ^[3] ; Zhenwei,Shen ^[4] ; Yifan,Zhang ^[2] ; Wei,Li ^[2] ; Jin,Yang ^[5] ; Yongqiang,Liu ^[6] ; Xiaojuan,Lai ^[6] ; Yanchun,Gong ^[6] ; Xuefang,Liu ^[6] ; Yongguo,Li ^[7] ; Dafang,Zhong ^[2] ; Junqi,Niu ^[8] ; Bin,Liu ^[9] ; Yanhua,Ding ^[1]

作者单位： Phase I Clinical Trial Unit, First Hospital, Jilin University, Jilin, China. ^[1] State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. ^[2] State Key Laboratory of Natural Medicines and Center of Drug Discovery, College of Pharmacy, China Pharmaceutical University, Nanjing, China. ^[3] First Hospital and Institute of Immunology, First Hospital, Jilin University, Jilin, China. ^[4] Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China. ^[5] Jiangsu Vcare PharmaTech Co. Ltd., Nanjing, China. ^[6] Hua Medicine Ltd., Shanghai, China. ^[7] Department of Hepatology, First Hospital, Jilin University, Jilin, China. ^[8] Department of Hand Surgery, First Hospital, Jilin University, Jilin, China. ^[9]

关键词 clopidogrel pharmacodynamics pharmacokinetics safety vicagrel

DOI 10.3389/fphar.2018.00643

PMID 29973877

发布时间 2020-10-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交